

Contact:

Epigenomics AG

Dr. Achim Plum

VP Corporate Communications

+49 30 24345 368

ir@epigenomics.com

Released May 4, 2007, 5:30 pm CET

page 1 of 2

Ad Hoc: Epigenomics AG Completes Capital Increase and Placement of New Shares

Berlin, Germany and Seattle, WA, USA - May 4, 2007 ●●● Epigenomics AG (Frankfurt, Prime Standard: ECX) today reported the successful placement of 1,335,526 new shares at a price of EUR 3.64 per share. The share capital increase was executed under exclusion of subscription rights. Gross proceeds to Epigenomics from the share issue are approximately EUR 4.9 million. After registration of this capital increase, the share capital of Epigenomics AG will increase from EUR 16,916,125 to EUR 18,251,651. Participants in the transaction included OrbiMed Advisors LLC (New York, NY, USA), Stephens Investment Management LLC (San Francisco, CA, USA), and a limited number of other institutional investors in Europe and institutional buyers and accredited investors the US.

Trout Capital LLC (New York, NY, U.S.A.) acted as sole placement agent in the U.S. and DZ Bank (Frankfurt, Germany) will coordinate the listing of the new shares. The new shares shall entitle the holders to partake in dividends as of January 1, 2007.

Epigenomics intends to use the issue proceeds to further develop its lead product, a molecular diagnostic test for the early detection of colorectal cancer, as well as its prostate and lung cancer programs.

End of ad hoc

"This financing will contribute to the advancement of our business and help fund the programs in our pipeline," commented Oliver Schacht, PhD, Chief Financial Officer of Epigenomics. "We are pleased to have attracted such a high quality group of investors in this offering on top of the placement of about 300,000 shares with our partner Affymetrix last summer."

Disclaimer relating to US Securities Laws

The sale of the common stock was not registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. The shares have been sold to a limited number of qualified institutional buyers and accredited investors pursuant to applicable exemptions from the registration requirements of the Securities Act. Unless registered, the shares may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities.

About Epigenomics AG

Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests can potentially diagnose disease at an early stage and help guide physicians to select an appropriate therapy. Epigenomics' defined business strategy covers two complementary core business areas:

In cooperation with industry partners, the company develops diagnostic screening tests for the early detection of cancer, mass-market products with huge potentials. Based on easily obtainable body fluid samples (e.g. blood and urine), these tests are aimed at finding cancer at an early stage before symptoms occur. Epigenomics' product pipeline contains an extensively validated biomarker panel for the early detection of colorectal cancer in blood plasma, and further proprietary DNA methylation biomarkers at various stages of development for prostate and lung cancer detection in body fluids.

Epigenomics aims at giving patients and doctors early access to these biomarkers through reference laboratory testing services. For development and global commercialization as in vitro diagnostic test kits, Epigenomics pursues a non-exclusive partnering strategy with diagnostics industry players.

As a second core business area, Epigenomics develops specialty diagnostics for individuals at high risk for cancer and cancer patients. These tests include surveillance applications of our colorectal cancer biomarkers and a tissue-based prognostic cancer molecular classification test for prostate cancer patients. Our tissue-based prostate cancer application is developed in strategic partnerships with Qiagen (pre-analytics) and Affymetrix (diagnostic device platform). The biomarkers for cancer specialty diagnostic applications will be made available through testing services in centralized reference laboratories. Epigenomics retains the flexibility to decide on further commercialization as in vitro diagnostic test kits in Europe and eventually the US..

Pharma, diagnostics and biotech partners can access Epigenomics' portfolio of proprietary DNA methylation technologies and biomarkers protected by more than 200 patent families through Biomarker Services, IVD Development Collaborations, and Licensing. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary in Seattle, WA, USA. For more information, please visit Epigenomics' website at www.epigenomics.com.

###

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.